NL-OMON46181已完成不适用
An open-label, mass balance study to investigate the absorption, metabolism and excretion of [14C]-PBI-4050 after a single 1200 mg oral dose to healthy male subjects - CS0304 Prometic
Prometic0 个研究点目标入组 6 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •The following criteria must be met by all subjects considered for study participation:
- •1. Able to provide informed consent to participate in this study after reading the participant information sheet and informed consent form and after having the opportunity to discuss the study with the Investigator or designee.
- •2. Healthy and free from clinically significant illness or disease as determined by medical history, physical examination, laboratory and other tests at Screening.
- •3. Male Caucasian subjects, aged 21 to 55 years (inclusive) at Screening.
- •4. A body weight of *60 kg and a body mass index ranging from 18 to 30 kg/m2 at Screening.
- •5. The subject must agree to minimize the risk of a female partner becoming pregnant from the dosing day until 3 months after the completion of the study. Acceptable methods of contraception for male volunteers include a vasectomy no less than 6 months prior to dosing, barrier contraception or a medically accepted contraceptive method. For female partners of male volunteers, acceptable methods of contraception include intra-uterine device, tubal ligation, hormonal contraceptive since at least two months and diaphragm with spermicide.
- •6. In the Investigator*s opinion, subject is able to understand the nature of the study and any risks involved in participation, and willing to cooperate and comply with the protocol restrictions and requirements.
排除标准
- •Subjects will be excluded if they meet any of the following criteria:
- •1. Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance.
- •2. History or current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hormonal disorders.
- •3. History of any major surgery within the last four weeks before participation in this study or any bone fracture within the last two months.
- •4. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders.
- •5. Chronic or relevant acute infections.
- •6. History of allergy/ hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator.
- •7. History of any bleeding disorder including prolonged or habitual bleeding, other hematologic disease or cerebral bleeding (e.g. after a car accident) or commotion cerebri.
- •8. Intake of drugs with a long half-life (>24 hours) within 1 month prior to study drug administration.
- •9. Use of any kind of prescription medication from 14 days prior to the administration of the study drug.
- •10. Use of over-the-counter products and/or natural health products (including food supplements, herbal supplements, etc.).
- •11. Participation in another trial with an investigational drug within 2 months prior to administration of the study drug or during the trial.
- •12. The subject is a smoker (>10 cigarettes or 3 cigars or 3 pipes/day) or uses other nicotine-containing products (for example, snuff, nicotine patches, nicotine chewing gum, mock cigarettes) or is unable to reform from smoking on study days. Ex-smokers must have ceased smoking *3 months prior to Screening.
- •13. Alcohol abuse (>60 g/day (6 units/day)).
- •14. History of drug abuse.
- •15. Blood donation within 3 months prior to administration or during the trial.
- •16. Any laboratory value outside the reference range, unless considered to lack clinical reference.
研究者
相似试验
进行中（未招募）
1 期
A study to investigate the uptake, distribution, breakdown and excretion of a single dose of [14C]-etripamil administered with a nasal spray in healthy volunteersParoxysmal supraventricular tachycardia (PSVT)EUCTR2019-004979-39-NLMilestone Pharmaceuticals Inc.8
已完成
不适用
An open-label, mass balance study to investigate the absorption, metabolism and excretion of [14C]-EYP001a after a single oral dose to healthy male subjectsChronic liver diseases, HBV/NASHchronic hepatitis B virus (HBV) infection and non-alcoholic steatohepatitis (NASH).NL-OMON48170ENYO Pharma SA6
已完成
不适用
An open-label, mass balance study to investigate the absorption, distribution, metabolism and excretion of [14C]-OTL0038 after a single intravenous dose to healthy volunteers.ovarian cancerNL-OMON48212On Target Laboratories, Inc8
已完成
不适用
Open-Label, Mass Balance Study to Investigate the Absorption, Distribution, Metabolism And Excretion Of [14C]-Etripamil Nasal Spray After a Single Dose to Healthy Male Subjects.NL-OMON50057Milestone Pharmaceuticals Inc8
进行中（未招募）
1 期
OP-724-001 studyHealthy volunteersJPRN-jRCT2031230432Yuushi Haruyama6